CenterBook Partners LP Makes New $5.14 Million Investment in Syndax Pharmaceuticals, Inc. $SNDX

CenterBook Partners LP acquired a new stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 273,253 shares of the company’s stock, valued at approximately $5,137,000. CenterBook Partners LP owned approximately 0.31% of Syndax Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Allworth Financial LP acquired a new stake in shares of Syndax Pharmaceuticals during the 2nd quarter worth $26,000. Sterling Capital Management LLC lifted its position in Syndax Pharmaceuticals by 846.6% during the third quarter. Sterling Capital Management LLC now owns 2,963 shares of the company’s stock worth $56,000 after purchasing an additional 2,650 shares during the period. Nykredit A S bought a new stake in Syndax Pharmaceuticals during the second quarter worth about $72,000. Integrated Wealth Concepts LLC bought a new stake in Syndax Pharmaceuticals during the second quarter worth about $73,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Syndax Pharmaceuticals during the third quarter worth about $86,000.

Wall Street Analysts Forecast Growth

SNDX has been the topic of a number of recent analyst reports. HC Wainwright decreased their price objective on shares of Syndax Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday. Jefferies Financial Group restated a “buy” rating and set a $35.00 target price on shares of Syndax Pharmaceuticals in a research note on Tuesday, September 29th. Bank of America reaffirmed a “buy” rating on shares of Syndax Pharmaceuticals in a report on Wednesday, August 5th. Mizuho set a $43.00 price target on Syndax Pharmaceuticals in a research note on Tuesday. Finally, JPMorgan Chase & Co. lowered their price target on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $41.60.

Key Headlines Impacting Syndax Pharmaceuticals

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Syndax expects 19 drug abstracts to be featured at ASH 2026, which may raise visibility for its oncology pipeline. The headlines do not disclose the data or establish whether the findings are favorable, so the abstracts are a potential catalyst rather than confirmed positive results. Article: Syndax Pharmaceuticals stock: ASH to feature 19 drug abstracts Article: Why Is Syndax Pharmaceuticals Drawing So Much ASH 2026 Attention?
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and $36 price target. Its revisions were mixed: it slightly improved some 2026 and longer-term estimates, but reduced its 2027 and 2028 forecasts. Analyst estimates and rating
• Neutral Sentiment: A Seeking Alpha analysis says Revuforj is showing strong commercial growth, but identifies potential frontline AML use as a key factor for the company’s outlook. Article: Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Syndax investors. The announcement does not provide details of the claims, but the investigation adds legal uncertainty and may weigh on sentiment. Article: Pomerantz Law Firm Investigates Claims On Behalf of Syndax Investors

Syndax Pharmaceuticals Price Performance

NASDAQ:SNDX traded up $0.17 on Friday, hitting $9.54. The company had a trading volume of 4,170,993 shares, compared to its average volume of 2,850,792. Syndax Pharmaceuticals, Inc. has a 52 week low of $9.22 and a 52 week high of $25.59. The company has a current ratio of 6.77, a quick ratio of 6.44 and a debt-to-equity ratio of 38.95. The stock has a market capitalization of $845.34 million, a price-to-earnings ratio of -4.04 and a beta of 0.48. The firm has a 50 day moving average of $16.33 and a two-hundred day moving average of $20.02.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05). Syndax Pharmaceuticals had a negative return on equity of 517.88% and a negative net margin of 72.32%. The company had revenue of $83.30 million for the quarter, compared to the consensus estimate of $81.38 million. During the same period in the previous year, the firm posted ($0.70) EPS. The business’s quarterly revenue was up 81.9% compared to the same quarter last year. On average, research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.08 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Dennis Podlesak sold 8,000 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Thursday, October 29th. The shares were sold at an average price of $14.21, for a total transaction of $113,680.00. Following the sale, the director directly owned 239,763 shares in the company, valued at $3,407,032.23. This trade represents a 3.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.80% of the stock is currently owned by corporate insiders.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.